Table 3. Summary treatment and relapse details for patient cohort.
| |
Response to MTX |
|
|---|---|---|
| Sensitive (n=461) | Resistant (n=339) | |
| Median MTX cycles received (range) |
7 (3–14) |
4 (3–11) |
|
Relapse | ||
| No | 442 (95.9%) | ND |
| Yes |
19 (4.1%) |
ND |
|
Second-line treatment | ||
| ACT-D | 0 (0%) | 164 (48.4%) |
| EMA-CO | 17 (89.5%) | 192 (51.6%) |
| Hysterectomy |
2 (10.5%) |
0 (0%) |
| Median time to second-line treatment (range) | 11.36 months (5.7–33.3) | 1.8 months (0.9–5.2) |
Abbreviations: ACT-D=actinomycin D; EMA-CO=etoposide, MTX, ACT-D, cyclophosphamide and vincristine regimen; MTX=methotrexate.